{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-014394","form_type":"8-K","ticker":null,"cik":"0001603207","company_name":"Notable Labs, Ltd.","filed_at":"2024-04-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:19.175847+00:00","generated_at":"2026-06-03T23:23:24.886294+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Notable Labs reports FY2023 net loss of $11.3M; cash of $8.2M as of Apr 1, 2024","bullets":["Net loss $11.3M ($3.41 per share) vs $14.4M in 2022; revenue $0.3M from diagnostic services.","Cash and equivalents $11.8M at Dec 31, 2023; $8.2M as of Apr 1, 2024; runway into Q4 2024.","R&D expenses fell to $4.7M from $7.8M; G&A rose to $10.1M from $5.2M due to merger costs.","Phase 2 volasertib/PPMP trial for r/r AML to start in coming months with dose-optimization lead-in.","Company became public via reverse merger in October 2023; shares outstanding ~9.0M as of Apr 1."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-014394","json":"https://secwatch.observer/filing/0001493152-24-014394.json","markdown":"https://secwatch.observer/filing/0001493152-24-014394.md","text":"https://secwatch.observer/filing/0001493152-24-014394.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1603207/000149315224014394/0001493152-24-014394-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1603207/000149315224014394/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T23:23:24.886294+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"723db0dd742736b1b7ca4eafd2264f3d2efe1efd","claim":"Notable Labs, Ltd. reported the year ended December 31, 2023 results: revenue $0.3 million, net income $(11.3) million, EPS $(3.41) per share.","evidence_excerpt":"Total net revenue includes revenue from diagnostic services performed on a limited basis as an outsourced provider. Total net revenue for the year ended December 31, 2023 was $0.3 million. Total cost of services relate to the costs of processing diagnostic tests of laboratory samples. Total cost of services for the year ended December 31, 2023 was $0.2 million.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1603207/000149315224014394/0001493152-24-014394-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2023"},{"label":"Revenue","value":"$0.3 million"},{"label":"Net income","value":"$(11.3) million"},{"label":"EPS","value":"$(3.41) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}